CCAR2 and osteosarcoma: Moreover, the inhibition of the proliferation and invasion activity of osteosarcoma cells with the knock-down of DBC1 or AR suggested that the DBC1-AR pathway could be usable as a new therapeutic target in the treatment of osteosarcoma patients.